ARTICLE | Clinical News
XTL Phase II HBV interim results
December 10, 2001 8:00 AM UTC
XTL Biopharmaceuticals (LSE:XTL) said in an ongoing 60-patient, placebo-controlled Phase IIa study of XTL-001 plus lamivudine, hepatitis B virus (HBV) DNA levels were lowered to an undetectable level ...